Skip to main content

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

Active, not recruiting · Not applicable · NCT04798768

Conditions: Tachycardia, Ventricular, Arrhythmia, Ventricular

At a glance

Research payments reported, 2025
$359,843
U.S. investigators named
15
Sites paid
16
Planned or actual enrollment
297

About the trial

Sponsor
Boston Scientific Corporation
Tested
mCRM Therapy System (device)
Dates
Started 2021-07-20; completion 2030-12-31
Results posted
Yes

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $359,843 in research payments for this study in 2025 (71 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.